14 Mar 22 | OcyonBio announced that it has entered into a manufacturing and operations agreement with Biosimilar Solutions Inc. to create a contract biosimilars development/manufacturing organisation (including process development, plasmid, vectors, cell banks, processing and testing facilities) in Puerto Rico. Biosimilar Solutions expects to manufacture recombinant proteins and monoclonal antibodies from 2022.
15 Mar 22 | Evio Pharmacy announced a roll-out of a biosimilar strategy to help make medicines affordable. Evio announced that it has contracted directly with biosimilars manufacturers for autoimmune disease and cancer therapeutics.
15 Mar 22 | The Centre for Biosimilars reported on a study on Celltrion’s CT-39 (biosimilar omalizumab) presented at the American Academy of Allergy Asthma and Immunology annual meeting. Celltrion reported that the study demonstrated equivalence with Xolair® (omolizumab).
15 March 22 | Merck announced that it will discontinue Ph III trials of Keytruda® (pembrolizumab) in combination with Lynparza® (olaparib) in patients with metastatic castration-resistant prostate cancer following the recommendation of an independent Data Monitoring Committee. Merck said that interim analysis indicated that the combination treatment did not demonstrate a benefit in overall survival.
17 Mar 22 | Merck announced results from Ph III trials of Keytruda® (pembrolizumab) in patients with Stage IB-IIIA non-small cell lung cancer, reporting that Keytruda® significantly improved disease-free survival.
Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance. Call us today on 02 9023 9988 or email info@pearceIP.law.